| pubmed-article:15319775 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15319775 | lifeskim:mentions | umls-concept:C0008059 | lld:lifeskim |
| pubmed-article:15319775 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:15319775 | lifeskim:mentions | umls-concept:C0679199 | lld:lifeskim |
| pubmed-article:15319775 | lifeskim:mentions | umls-concept:C1705576 | lld:lifeskim |
| pubmed-article:15319775 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:15319775 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:15319775 | pubmed:dateCreated | 2004-8-20 | lld:pubmed |
| pubmed-article:15319775 | pubmed:abstractText | Regimen-related toxicity (RRT) is a frequent cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (HSCT). In this pilot study, we examined the feasibility and potential efficacy of administering a fixed combination of agents as a novel approach to reducing RRT in children undergoing HSCT. Thirty-seven patients were treated with ursodeoxycholic acid, folinic acid, vitamin E, and parenteral nutrition titrated to measured energy expenditure in the peritransplantation period. Outcomes were compared with those in historical controls (n = 131). Compliance with oral ursodeoxycholic acid and vitamin E of at least 90% was achieved in a mean of 86% (95% confidence interval, 75%-97%) of patients. In the study group, we observed (1) reduced prevalence and severity of mucositis (P = .008 and.004, respectively); (2) less severe hepatic toxicity (P = .007); and (3) shorter time to engraftment (P = .02) compared with the control group. These benefits appeared most pronounced among high-risk patients. The administration of this regimen, including oral medications, is feasible during the peritransplantation period, and it is well tolerated. The decreased RRT observed in comparison to historical controls suggests that combination approaches deserve exploration as a means of reducing the morbidity of HSCT. | lld:pubmed |
| pubmed-article:15319775 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15319775 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15319775 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15319775 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15319775 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15319775 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:15319775 | pubmed:issn | 1083-8791 | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:RichardsonPau... | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:ThornleyIanI | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:SungLillianL | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:DugganChristo... | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:GuinanEva CEC | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:VangelMarkM | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:LehmannLeslie... | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:HolmesColleen... | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:BrennanLisaL | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:SpearJan MJM | lld:pubmed |
| pubmed-article:15319775 | pubmed:author | pubmed-author:BechardLori... | lld:pubmed |
| pubmed-article:15319775 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15319775 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:15319775 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15319775 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15319775 | pubmed:pagination | 635-44 | lld:pubmed |
| pubmed-article:15319775 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:meshHeading | pubmed-meshheading:15319775... | lld:pubmed |
| pubmed-article:15319775 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15319775 | pubmed:articleTitle | A multiagent strategy to decrease regimen-related toxicity in children undergoing allogeneic hematopoietic stem cell transplantation. | lld:pubmed |
| pubmed-article:15319775 | pubmed:affiliation | Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA. | lld:pubmed |
| pubmed-article:15319775 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15319775 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15319775 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
